NORD gratefully acknowledges Kristina Bundra, Pharm. D, NORD Editorial Intern, and Chester V. Oddis, MD, Professor of Medicine, University of Pittsburgh School of Medicine, for assistance in the preparation of this report.
Polymyositis (PM) and necrotizing myopathy (NM) are two types of inflammatory myopathy characterized by characteristic features on a muscle biopsy. PM has more inflammatory changes in the muscle tissue, while NM has more necrosis and degeneration of the muscle fibers. Both lead to symmetric weakness and some degree of muscle wasting (atrophy). The muscles that are principally affected include those closest to and within the trunk of the body such as the hip, shoulders, arms, pharynx and neck. PM occurs most often in women over 20 years of age, but men can also be affected. NM can occur in all age groups and is very rarely seen as a complication of the statin drugs used to lower the serum cholesterol. Muscle weakness usually happens over days, weeks or months. Some affected people have muscle pain, breathing problems, and trouble swallowing.
The inflammatory myopathies are a group of diseases that involve chronic muscle inflammation and weakness. They are thought to be autoimmune diseases, meaning the body’s natural defenses (antibodies, lymphocytes, etc.) against invading organisms begin to attack perfectly healthy tissue for unknown reasons, leading to inflammation or swelling. Over the past several years, PM has been less frequently diagnosed as more patients are being classified as having necrotizing myopathy (NM) or an overlap of myositis with another autoimmune disease. NM has similar clinical features compared to PM and is distinguished by the characteristic histopathological findings noted above. Further, NM patients often have characteristic autoantibodies in their blood that can be detected using specialized laboratory testing.
The symptoms of PM and NM may start gradually or suddenly and often wax and wane for no apparent reason.
The major symptom of the disorder is muscle weakness, most often in the hip and shoulder areas, eventually making it difficult for patients to lift their arms, get out of a chair or to climb steps. Other muscles which may be affected are the neck and throat muscles, which may result in difficulty swallowing and cause changes in the voice due to muscle weakness. Rarely, chest muscles are affected.
The muscle weakness may appear suddenly and progress over weeks to months. Additionally, the degree of muscle weakness may fluctuate over time as well. The muscles of the hands, feet and face are rarely involved in PM or NM, but generalized muscle pain may occur. Atrophy (loss of bulk) of muscle and contractures of the muscle around larger joints may develop late in the chronic stage.
Other symptoms of PM and NM may include weight loss and fatigue, and patients with PM or the overlap syndrome noted above may also have fever, joint pain and Raynaud phenomenon which is a sensitivity to the cold that is most often felt in the fingers. Raynaud phenomenon is caused by constriction (narrowing) of the blood vessels in the fingers upon exposure to the cold. Cracking of the fingers, termed “mechanic’s hands” may also develop in PM and overlap disorders and this skin problem is associated with certain autoantibodies which circulate in the blood of affected patients.
The joint pain seen in PM (called polyarthralgia) may be accompanied by swelling and mimic the findings seen in patients with rheumatoid arthritis but generally these rheumatic complaints are mild and respond well to glucocorticoids (i.e. prednisone). Gastrointestinal involvement in both PM and NM can lead to difficulty swallowing as the muscles involved in swallowing can become inflamed and weak, and the esophagus can be affected leading to heartburn but lower GI involvement is uncommon. Involvement of the heart, detected chiefly by irregularities in the electrocardiogram (ECG), has been reported but inflammation and weakening of the heart muscle (myocarditis) is rare.
Interstitial lung disease is a serious complication seen in PM and the overlap myositis disorders but is uncommon in NM and leads to cough with shortness of breath as inflammation occurs in the lung tissue. This may progress to scarring (fibrosis) of the lung tissue making the lungs stiff and inelastic. In some patients, lung disease may precede myositis and dominate the clinical picture.
Symptoms in both PM and NM may worsen during pregnancy in women whose disease is active increasing the risk of premature birth or stillbirth.
As noted above, PM can occur in overlap with other autoimmune or rheumatic diseases, including Sjogren syndrome or scleroderma (systemic sclerosis). In addition, malignancy may complicate the course and presentation of PM or NM but is more common in dermatomyositis. This is more common in males and females over the age of 50.
Abdominal symptoms, more common in children with juvenile dermatomyositis (JDM), may be associated with the passage of dark stools or the vomiting of blood from gastrointestinal ulcerations that may progress to perforation and require surgical intervention. Calcinosis (the deposition of calcium deposits in the skin and soft tissue or muscle) is also more frequent in JDM.
The exact cause of PM and NM is unknown. Like other autoimmune diseases, the body’s natural immune defense mechanisms attack its own tissue. Exposure to certain drugs has been shown to increase the likelihood of developing myositis and a common drug known to induce NM are the statin agents and a specific autoantibody (anti-HMGCR) has been found to be associated with statin-associated NM. In PM and overlap myositis disorders, the autoimmune attack on muscle tissue can occur through a T-cell mediated destructive process directed against unidentified muscle antigens, but the finding of myositis-specific autoantibodies in many PM and overlap myositis patients also supports disorders associated with B cells.
The injection of collagen for cosmetic use has been implicated in the onset of a polymyositis-like syndrome. Injectable bovine collagen has been used to reduce wrinkles and facial scars, usually in women. The onset of PM in such patients is felt to result from an autoimmune reaction to the collagen.
PM and NM may appear at any time from infancy through the age of 80 years, but most commonly occurs in adults over 20 years of age, especially those aged 45 to 60 years. Juvenile PM is very rare (much less common than juvenile DM) and the symptoms usually appear between the ages of five to 15 years. Females are affected twice as often as males and PM is more common in African Americans than in Caucasians.
The diagnosis of PM is often delayed due to the lack of physical findings before the onset of muscle disease. Both family history and medication history are important in excluding other causes of myopathy. Additionally, various tests may be performed to establish a diagnosis. Tests may include: (a) electromyography done by a specialist in neuromuscular diseases which detects characteristic electrical patterns in muscle tissue and are abnormal in almost all patients with polymyositis; (b) muscle biopsy which reveals inflammation and or necrosis in the muscle tissue; (c) magnetic resonance imaging (MRI) of the affected muscle(s) which demonstrates inflammation and edema within the muscle tissue. Blood tests can be performed to detect elevated levels of muscle enzymes, predominantly creatine kinase (CK) and aldolase among others, which are indicative of muscle damage. Autoantibodies have been identified in many PM and NM patients consistent with an autoimmune cause as discussed earlier.
Polymyositis generally responds well to treatment in most patients, although, residual weakness may occur in approximately 30% of patients.
Glucocorticoids (i.e. steroids or prednisone) are widely used as the initial form of treatment in PM. They control the inflammation, lessen pain, and increase muscle strength through their ability to suppress the body’s immune system. The specific dose is individualized; however, the starting dose of prednisone is generally high at about 1mg/kg of body weight (often equating to about 60mg/day). They are then tapered depending on the response of the patient and associated side effects. Measurement of the serum CK is used to gauge the effectiveness of therapy and reduction of the muscle enzymes to normal values is noted in a majority of patients with this disorder within 4 to 8 weeks after treatment is started. This is followed by an improvement in muscle strength. As the steroids are reduced (or often initially when the steroids are started) other medications that also suppress the immune system may be added so that the glucocorticoids can be tapered. This is necessary to reduce the side effects (i.e. osteoporosis, weight gain, change in mental status, increased blood sugar, cataracts, stomach upset, etc.) that the steroids cause. In many cases of adult PM and NM prolonged maintenance therapy with prednisone or other immunosuppressive agents may be necessary indefinitely. A major concern with glucocorticoids is osteoporosis, which may cause significant morbidity. In this instance, additional calcium and vitamin D supplementation may be beneficial.
Immunosuppressive drugs such as methotrexate, azathioprine, mycophenolate mofetil, tacrolimus, cyclosporine cyclophosphamide, and others have been beneficial to patients who fail to respond to steroids alone and can be used as second-line therapies or in combination with prednisone. Cyclophosphamide and tacrolimus are used more frequently in patients with interstitial lung disease.
Acthar is a synthetic adrenocorticotropic hormone (ACTH) that is FDA-approved for the treatment of polymyositis and dermatomyositis but the exact mechanism of action is unknown and this agent acts through melanocortin receptors. Currently, there is limited data on its effectiveness. Intravenous immunoglobulin (IVIG) is a blood product that enhances the body’s immune system response. IVIG is usually used in patients who do not respond to other therapies but has been noted to be particularly effective in NM. Biologic agents provide a more targeted therapy and are often monoclonal antibodies or proteins targeting various immune system mediators. Anti-tumor necrosis factor (anti-TNF) agents such as etanercept, adalimumab, and infliximab have potential for use in polymyositis as they suppress tumor-necrosis factor proteins that are associated with inflammation but data supporting their effectiveness are limited. Rituximab is another biologic monoclonal antibody that targets B cells which play a role in inflammation. This agent has been studied in treating PM, DM and NM and may provide some benefit to these patients; however, more studies are required.
Various vitamins and supplements, although not approved specifically for use in polymyositis, have been useful to patients. Examples include: coenzyme Q10 (CoQ10), creatine, fish oil, and others.
Physical therapy and a regular exercise routine are often recommended even when the myositis is active as the beneficial effects of exercise are being increasingly reported. Patients also benefit from heat therapy, passive range-of-motion exercises, and splints to avoid contractures. Speech therapy may be useful if the swallowing muscles become weakened. Additionally, a registered dietitian can be recommended if chewing and swallowing become problematic.
Information on current clinical trials is posted on the Internet at www.clinicaltrials.gov. All studies receiving U.S. government funding, and some supported by private industry, are posted on this government web site.
For information about clinical trials being conducted at the NIH Clinical Center in Bethesda, MD, contact the NIH Patient Recruitment Office:
Tollfree: (800) 411-1222
TTY: (866) 411-1010
Email: [email protected]
Some current clinical trials also are posted on the following page on the NORD website:
For information about clinical trials sponsored by private sources, contact:
For information about clinical trials conducted in Europe, contact:
A unit of the National Institute of Environmental Health Sciences, called the Environmental Autoimmunity Group, has been established at the NIH to conduct pioneering research in understanding the genetic and environmental risk factors that may result in autoimmune disease. For information about current or ongoing studies, visit: http://www.niehs.nih.gov/research/atniehs/labs/crb/pi/ea/
Senecal J, Raynauld J, Troyanov Y. A New Classification of Adult Autoimmune Myositis. Arthritis and Rheumatology, 2017 69(5): 878-884.
Oddis CV, Aggarwal R. Treatment in Myositis. Nat Rev Rheumatol, 2018 14(5): 279-289.
Seetharaman M. Polymyositis: Treatment and Management. Medscape.Updated: Feb 12, 2018. Available at: http://emedicine.medscape.com/article/335925-overview Accessed April 2, 2019.
Polymyositis. The Myositis Association. Updated January 2015. Available at: http://www.myositis.org/learn-about-myositis/types-of-myositis/polymyositis Accessed April 2, 2019.
Polymyositis – Adult. The National Institute of Medicine: Medline Plus. Review Date 2/8/2017 Available at: http://www.nlm.nih.gov/medlineplus/ency/article/000428.htm Accessed April 2, 2019.
Polymyositis. The Mayo Clinic. June 24, 2014. Available at: http://www.mayoclinic.org/diseases-conditions/polymyositis/basics/definition/con-20020710 Accessed April 2, 2019.
The information in NORD’s Rare Disease Database is for educational purposes only and is not intended to replace the advice of a physician or other qualified medical professional.
The content of the website and databases of the National Organization for Rare Disorders (NORD) is copyrighted and may not be reproduced, copied, downloaded or disseminated, in any way, for any commercial or public purpose, without prior written authorization and approval from NORD. Individuals may print one hard copy of an individual disease for personal use, provided that content is unmodified and includes NORD’s copyright.
National Organization for Rare Disorders (NORD)
55 Kenosia Ave., Danbury CT 06810 • (203)744-0100